| Description | MK-8325 is a potent and orally available HCV NS5A inhibitor with replicative activity against a wide range of genotypes.MK-8325 has demonstrated bioavailability in in vitro and in vivo assays and has a favorable overall ADME profile. |
| In vitro | MK-8325 (7 μM) 在标准MTS测定中对Huh-7复制子细胞表现出CC50 > 25 mM，说明其没有细胞毒性。[1] |
| In vivo | 体内实验显示，MK-8325 口服生物利用度高，其药动学特性适合患者每日一次给药，并且整体具有良好的ADME特性。[1] |
| Synonyms | MK 8325, MK8325 |
| molecular weight | 915.93 |
| Molecular formula | C43H54Cl2F2N8O6Si |
| CAS | 1334314-19-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 9.16 mg/mL (10 mM) |
| References | 1. Nair AG, et al. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV. Bioorg Med Chem Lett. 2018;28(10):1954-1957. 2. Yu W, et al. Discovery of potent macrocyclic HCV NS5A inhibitors. Bioorg Med Chem Lett. 2016;26(15):3793-3799. |